Coya Therapeutics (COYA) Evercore ISI 8th Annual HealthCONx Conference summary

Key accomplishments in 2025

• Lead asset advanced into a potentially registration-enabling clinical trial phase.

• Interim data from an investigator-initiated trial in frontotemporal dementia showed promising results.

• Preclinical data demonstrated synergistic potential of GLP-1s with proprietary low-dose interleukin-2 (COYA 301).

• Scientific advisory board member awarded Nobel Prize, providing external validation of the scientific approach.

Platform and scientific approach

• Focused on neurodegenerative diseases by restoring Treg numbers and function to reduce inflammation.

• Utilizes a combination biologic approach with low-dose interleukin-2 and CTLA-4 to sustain Treg function.

• Consistent results across small trials in ALS, FTD, and Alzheimer's support the approach.

Clinical development and trial design

• ALS phase II trial is a randomized, double-blind, placebo-controlled study with 120 patients and a six-month primary endpoint (ALSFRS).

• Secondary endpoints include neurofilament light and oxidative stress biomarkers.

• Trial design includes stratification by neurofilament light and a re-randomization extension for further data.